Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TC Biopharm (Holdings) PLC TCBP

Healthcare Biotechnology
TC BioPharm (Holdings) plc, formerly TC BioPharm (Holdings) Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapy products that are based on its allogeneic gamma delta T (GD-T) cell platform. Harnessing the innate ability of GD-Ts, the Company has developed a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, it is also developing a range of genetically modified chimeric antigen receptor modified T cell (CAR-T) products for treatment of solid cancers. The Company’s pipeline includes OmnImmune, ImmuniStim, TCB009, and TCB005/TCB006. OmnImmune is an allogeneic unmodified GD-T (GD-T2) cell product, used for the treatment of Acute Myeloid Leukaemia (AML). ImmuniStim is used for the treatment of coronavirus disease (COVID-19). TCB009 is developing GD-T2 based cell therapies.


NDAQ:TCBP - Post by User

TC Biopharm (Holdings) PLC
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(291)
•••
Post by whytestockson Oct 03, 2024 10:45am
45 Views
Post# 36251624

TCBP Announces Artificial Intelligence Initiative with Partn

TCBP Announces Artificial Intelligence Initiative with Partn
NEWS: $TCBP TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor ScreeningTCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening PR Newswire TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the don...TCBP - TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities